HighGravityDataHologic — Nov 4, 2024 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001140361-24-045107
Showing in the filing
Non-GAAP EPS Reported % Increase (Decrease)
“4.2% to 6.6%”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 24
Accelerated share repurchase (ASR) agreement for Q1 FY2025
“$250 million”
Anticipated closing of Gynesonics acquisition for FY2025
“first half of calendar year 2025”
Non-GAAP tax rate ( basis) for FY2025
“approximately 19.5%”
Non-GAAP tax rate for FY2024
“approximately 19.5%”
Diluted shares outstanding ( basis) for FY2025
“approximately 235 million”
Diluted shares outstanding for FY2024
“approximately 235 million”
Revenue for FY2025
“$4,150 - $4,200”
Revenue Reported % Increase (Decrease) for FY2025
“3.0% to 4.2%”
Revenue Constant Currency % Increase (Decrea… for FY2025
“2.3% to 3.5%”
Revenue Organic % Increase (Decrease) for FY2025
“1.7% to 3.0%”
Revenue Organic excluding COVID-19 % Increas… for FY2025
“3.4% to 4.7%”
GAAP EPS for FY2025
“$3.53 - $3.63”
GAAP EPS Reported % Increase (Decrease) for FY2025
“6.3% to 9.3%”
Non-GAAP EPS for FY2025
“$4.25 - $4.35”
Non-GAAP EPS Reported % Increase (Decrease) for FY2025
“4.2% to 6.6%”
Revenue for Q1 FY2025
“$1,025 - $1,035”
Revenue Reported % Increase (Decrease) for Q1 FY2025
“1.2% to 2.2%”
Revenue Constant Currency % Increase (Decrea… for Q1 FY2025
“0.4% to 1.4%”
Revenue Organic % Increase (Decrease) for Q1 FY2025
“(0.2%) to 0.8%”
Revenue Organic excluding COVID-19 % Increas… for Q1 FY2025
“1.8% to 2.8%”
GAAP EPS for Q1 FY2025
“$0.81 - $0.84”
GAAP EPS Reported % Increase (Decrease) for Q1 FY2025
“(21.4%) to (18.4%)”
Non-GAAP EPS for Q1 FY2025
“$1.00 - $1.03”
Non-GAAP EPS Reported % Increase (Decrease) for Q1 FY2025
“2.0% to 5.1%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Current Guidance
Guidance $
Reported %
Increase
(Decrease)
Constant Currency
% Increase
(Decrease)
Organic % Increase
(Decrease)
Organic excluding
COVID-19 % Increase
(Decrease)
Fiscal 2025
Revenue
$4,150 - $4,200
3.0% to 4.2%
2.3% to 3.5%
1.7% to 3.0%
3.4% to 4.7%
GAAP EPS
$3.53 - $3.63
6.3% to 9.3%
Non-GAAP EPS
$4.25 - $4.35
4.2% to 6.6%
Q1 2025
Revenue
$1,025 - $1,035
1.2% to 2.2%
0.4% to 1.4%
(0.2%) to 0.8%
1.8% to 2.8%
GAAP EPS
$0.81 - $0.84
(21.4%) to (18.4%)
Non-GAAP EPS
$1.00 - $1.03
2.0% to 5.1%
3
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding
COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net income margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROIC.
Organic revenue for the fiscal fourth quarter of 2024 excludes the divested Blood Screening and SSI ultrasound imaging businesses and the acquired Endomagnetics business. Revenue from acquired businesses is generally included
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.